Tirzepatide Research Dosing Escalation Protocol

Tirzepatide Research Dosing: Reference Guide

All dosing information in this guide is derived from published SURMOUNT and SURPASS clinical trial protocols and is provided for research reference only.

SURMOUNT Standard Escalation Protocol

The SURMOUNT-1 trial used a 20-week escalation to reach the 15mg maximum dose, with 4 weeks at each dose level:

Week

Dose

Weekly Amount

1–4	2.5 mg/week	10 mg/month
5–8	5 mg/week	20 mg/month
9–12	7.5 mg/week	30 mg/month
13–16	10 mg/week	40 mg/month
17–20	12.5 mg/week	50 mg/month
21+	15 mg/week	60 mg/month

Total tirzepatide used in escalation phase (weeks 1-20): 10+20+30+40+50 = 150 mg At maintenance (15mg/week): 60 mg/month, 720 mg/year

Supply Planning for Standard Escalation

Phase

Weeks

Total mg Needed

Recommended Supply

Escalation only	1–20	150 mg	2× 60mg vials or 1× 5-pack 20mg + 1× 60mg
Escalation + 8 wks maintenance	1–28	270 mg	1× 5-pack 20mg + 1× 60mg + 1× 30mg
Full SURMOUNT-1 (72 weeks)	1–72	~3,060 mg	Multiple orders required	Simplified 3-Step Escalation Protocol Some SURPASS sub-studies used an accelerated 3-step escalation, trading tolerability for speed:	Week	Dose

1–4	5 mg/week
5–8	10 mg/week
9+	15 mg/week

Total escalation phase: 8 weeks, 60 mg consumed Tradeoff: Higher GI adverse event rates during escalation, particularly nausea and vomiting in weeks 1-4.

Conservative Extended Escalation (8 weeks per dose level)

For research prioritising tolerability over speed to maximum dose:

Weeks

Dose

1–8	2.5 mg/week
9–16	5 mg/week
17–24	7.5 mg/week
25–32	10 mg/week
33–40	12.5 mg/week
41+	15 mg/week	Total to reach maximum dose: 40 weeks. GI adverse events are substantially reduced but time-to-maximum-efficacy is extended. Dose-Response Efficacy Data (SURMOUNT-1) Body weight reduction at 72 weeks by dose:	Dose	Mean Body Weight Reduction	≥5% Responders	≥20% Responders

5 mg/week

−16.0%

89%

32%

10 mg/week

−21.4%

96%

50%

15 mg/week

−22.5%

96%

57%

Placebo

−2.4%

28%

1%

The marginal gain from 10mg → 15mg is modest (−1.1 pp) compared to 5mg → 10mg (−5.4 pp). Some research protocols use 10mg as the target dose to balance efficacy and tolerability. Reconstitution Volume Reference For 15mg Vials (Standard Escalation)

BAC Water Added

Concentration

2.5mg dose

5mg dose

7.5mg dose

10mg dose

12.5mg dose

15mg dose

1.0 mL

15 mg/mL

0.17 mL

0.33 mL

0.50 mL

0.67 mL

0.83 mL

1.0 mL

For 20mg Vials (5-Pack)

BAC Water Added

Concentration

5mg dose

10mg dose

15mg dose

20mg dose

1.0 mL	20 mg/mL	0.25 mL	0.50 mL	0.75 mL	1.0 mL
2.0 mL	10 mg/mL	0.50 mL	1.0 mL	1.5 mL	2.0 mL

For escalation doses (2.5–7.5mg), use 2.0 mL BAC water to enable precise small-volume measurements.

Managing GI Adverse Events in Research Protocols

Nausea, diarrhea, and vomiting are the primary adverse events in tirzepatide research, concentrated in the first 4 weeks of each new dose level.

Protocol-Level Interventions

• Dose level timing: If GI symptoms are significant at a new dose, extending the current dose level by 4 additional weeks before escalating is the standard SURMOUNT protocol modification
• Injection timing: Some research protocols administer doses with a meal to reduce nausea severity
• Dose reduction: If escalation to the target dose proves poorly tolerated, maintaining the previous well-tolerated dose as the maintenance dose is a valid protocol endpoint

Expected Timeline for GI Event Resolution

Based on SURMOUNT adverse event data:

• Peak nausea: weeks 1-2 of each new dose level
• Significant reduction by week 4 of each dose level
• Near-baseline GI tolerability by week 8 of each dose level

The slow escalation protocol (8 weeks/step) nearly eliminates dose-change nausea for most subjects at the cost of doubling time to maximum dose.

Injection Technique for Research Protocols

Tirzepatide is administered as a subcutaneous (SC) injection in SURMOUNT trials:

• Sites: Abdomen (avoid 2-inch radius around navel), anterior thigh, or upper arm
• Rotation: Rotate sites with each injection to prevent lipodystrophy
• Needle: 28-31G, ½-inch needle for insulin syringe
• Injection speed: Slow, steady — 5-10 seconds for the injection volume
• Post-injection: Hold needle in place for 5 seconds before withdrawal to prevent leakage

Missed Dose Protocol (from SURMOUNT trial design)

From SURMOUNT trial protocol:

• If dose missed within 4 days of scheduled injection: administer as soon as possible, resume normal schedule
• If dose missed >4 days from scheduled injection: skip the missed dose, continue on normal schedule
• Do not administer two doses to compensate for a missed dose

Supply Calculation Worksheet

For a custom research protocol, calculate total tirzepatide needed:

Step 1: Sum the escalation phase consumption:

• (Number of weeks at each dose level) × (dose in mg)

Step 2: Add maintenance phase consumption:

• (Number of maintenance weeks) × 15mg (or target maintenance dose)

Step 3: Add 5-10% overage for reconstitution waste

Example — 16-week escalation (standard, skipping 2.5mg) + 8 weeks at 15mg maintenance:

• Escalation: (4×5) + (4×7.5) + (4×10) + (4×12.5) = 20 + 30 + 40 + 50 = 140mg
• Maintenance: 8×15 = 120mg
• Total: 260mg (+10% = 286mg)
• Best supply: 1× 5-pack 20mg (100mg) + 3× 60mg (180mg) = 280mg total